title: Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease.
abstract: BACKGROUND
  Gastrointestinal complaints are common in patients with kidney failure. The aim of this study was to investigate the effect of creatinine clearance on Helicobacter pylori (HP) eradication rate in patients with peptic ulcer disease.
  
  
  METHODS
  In this clinical trial, 132 patients with a range of kidney function (normal to end-stage renal disease) and peptic ulcer disease with HP infection were enrolled and divided into 5 groups by their creatinine clearance. For all patients, a 14-day standard regimen of triple therapy for peptic ulcer was started with omeprazole, 20 mg; clarithromycin, 500 mg; and amoxicillin, 1 g; twice per day. After 6 weeks, HP eradication rate were evaluated and compared between the groups with urea breath test.
  
  
  RESULTS
  The mean age of the participants was 44.84 ± 12.20 years and 68 (51.5%) were women. The five groups were not significantly different in terms of age, sex distribution, or body mass index. The results of urea breath test at 6 weeks were positive in 23 patients (17.4%). There was no significant difference in HP eradication rate (negative urea breath test) between the five groups.
  
  
  CONCLUSIONS
  This study showed no association between the success rate of eradication of HP infection and kidney function.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Alimadadi
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Seyyedmajidi
authors.affiliation: Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran. drsam74ir@ymail.com.
authors.forename: Saeid
authors.initials: S
authors.lastname: Amirkhanlou
authors.forename: Ali Akbar
authors.initials: AA
authors.lastname: Hafezi
authors.forename: Saba
authors.initials: S
authors.lastname: Homapour
authors.forename: Jamshid
authors.initials: J
authors.lastname: Vafaeimanesh
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Vakili
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001944:Breath Tests; D017291:Clarithromycin / Q000627:therapeutic use; D003404:Creatinine / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D003404:Creatinine; D017291:Clarithromycin; D009853:Omeprazole